CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
Hong Kong · Delayed Price · Currency is HKD 0.8600
+0.0100 (1.18%)
Jul 16, 2025, 4:08 PM HKT
HKG:0775 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 5,523 | 5,323 | 5,276 | 5,402 | 4,943 | Upgrade | |
Revenue Growth (YoY) | 3.76% | 0.89% | -2.35% | 9.30% | -0.49% | Upgrade |
Cost of Revenue | 3,830 | 3,686 | 3,650 | 3,772 | 3,536 | Upgrade |
Gross Profit | 1,693 | 1,637 | 1,626 | 1,630 | 1,407 | Upgrade |
Selling, General & Admin | 655.4 | 593.38 | 536.56 | 571.56 | 540.55 | Upgrade |
Other Operating Expenses | 867.98 | 723.86 | 747.93 | 707.51 | 674.36 | Upgrade |
Operating Expenses | 1,615 | 1,413 | 1,386 | 1,393 | 1,322 | Upgrade |
Operating Income | 77.46 | 223.85 | 239.92 | 236.61 | 84.75 | Upgrade |
Interest Expense | -337.18 | -322.43 | -163.09 | -97.82 | -128.73 | Upgrade |
Interest & Investment Income | 13.9 | 13.18 | 5.78 | 1.43 | 2.37 | Upgrade |
Earnings From Equity Investments | 0.15 | 0.33 | 0.02 | 1.21 | 1.48 | Upgrade |
Currency Exchange Gain (Loss) | -4.2 | -11.52 | -3.48 | 4.21 | 8.15 | Upgrade |
Other Non Operating Income (Expenses) | 45.08 | 31.52 | 27.79 | 28.77 | 2.69 | Upgrade |
EBT Excluding Unusual Items | -204.8 | -65.06 | 106.95 | 174.4 | -29.29 | Upgrade |
Gain (Loss) on Sale of Investments | 5.4 | -0.35 | 0.52 | -1.05 | -3.92 | Upgrade |
Gain (Loss) on Sale of Assets | 244.83 | 94.63 | 51.51 | -0.76 | -1.8 | Upgrade |
Asset Writedown | -136.91 | 39.37 | 43.72 | 61.13 | 132.21 | Upgrade |
Other Unusual Items | - | - | 2.16 | 4.52 | 21.92 | Upgrade |
Pretax Income | -91.48 | 68.58 | 204.86 | 238.24 | 119.13 | Upgrade |
Income Tax Expense | 35.07 | 51.33 | 72.91 | 75.44 | -6.1 | Upgrade |
Earnings From Continuing Operations | -126.55 | 17.25 | 131.95 | 162.8 | 125.23 | Upgrade |
Minority Interest in Earnings | - | - | 0.01 | - | 0.01 | Upgrade |
Net Income | -126.55 | 17.25 | 131.96 | 162.8 | 125.23 | Upgrade |
Net Income to Common | -126.55 | 17.25 | 131.96 | 162.8 | 125.23 | Upgrade |
Net Income Growth | - | -86.93% | -18.94% | 30.00% | -31.09% | Upgrade |
Shares Outstanding (Basic) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | Upgrade |
Shares Outstanding (Diluted) | 9,611 | 9,611 | 9,611 | 9,611 | 9,611 | Upgrade |
EPS (Basic) | -0.01 | 0.00 | 0.01 | 0.02 | 0.01 | Upgrade |
EPS (Diluted) | -0.01 | 0.00 | 0.01 | 0.02 | 0.01 | Upgrade |
EPS Growth | - | -86.93% | -18.94% | 30.29% | -31.22% | Upgrade |
Free Cash Flow | 157.01 | 226.51 | 147.64 | 207.37 | 195.52 | Upgrade |
Free Cash Flow Per Share | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | Upgrade |
Dividend Per Share | - | - | 0.008 | 0.010 | 0.010 | Upgrade |
Dividend Growth | - | - | -20.00% | - | - | Upgrade |
Gross Margin | 30.65% | 30.76% | 30.82% | 30.17% | 28.46% | Upgrade |
Operating Margin | 1.40% | 4.21% | 4.55% | 4.38% | 1.71% | Upgrade |
Profit Margin | -2.29% | 0.32% | 2.50% | 3.01% | 2.53% | Upgrade |
Free Cash Flow Margin | 2.84% | 4.25% | 2.80% | 3.84% | 3.96% | Upgrade |
EBITDA | 243.94 | 380.71 | 393.78 | 400.34 | 226.35 | Upgrade |
EBITDA Margin | 4.42% | 7.15% | 7.46% | 7.41% | 4.58% | Upgrade |
D&A For EBITDA | 166.47 | 156.86 | 153.86 | 163.73 | 141.6 | Upgrade |
EBIT | 77.46 | 223.85 | 239.92 | 236.61 | 84.75 | Upgrade |
EBIT Margin | 1.40% | 4.21% | 4.55% | 4.38% | 1.71% | Upgrade |
Effective Tax Rate | - | 74.85% | 35.59% | 31.66% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.